The overarching goal of MULTIR is to enhance survival rates through personalized treatment, achieved by predicting optimal therapeutic approaches based on host-tumor interaction models and facilitating targeted manipulation of these interactions to improve therapy response. Aligned with the Cancer Mission objectives set forth by the EU, the identified associations between tumors and hosts, along with a systematic comprehension of molecular and host-related factors affecting therapy response, will inform the development of AI-based tools (apps). These tools, created in collaboration with patients, guideline committee members, and regulators, will undergo testing in vivo, in vitro, and ex vivo, followed by assessment in clinical trials. By advancing personalized treatments, these tools aim to promote more strategic therapy utilization, mitigating potential toxic effects and socioeconomic burdens.